Reivindicaciones

CLAIMS 1. Nanoparticle conjugated with a peptide consisting of SEQ ID NO: 1, characterized in that the nanoparticle size is comprised between 100 and 150 nm, the Poly dispersity Index (PDI) is lower than 0.3 and the ratio between the total amount of the peptide and the total amount of lipids in the nanoparticle is comprised within 1 :5 and 1 : 15. 2. Nanoparticle conjugated with a peptide consisting of SEQ ID NO: 1, according to claim 1, characterized in that it comprises a PEG coating and mal eimide linking point, to enhance the pharmacokinetic properties and to enable the linking of SEQ ID NO: 1 peptide, respectively. 3. Nanoparticle conjugated with a peptide consisting of SEQ ID NO: 1, according to any of the previous claims, characterized in that it comprises a dye which allows the visualization of the nanoparticle by fluorescence imaging. 4. Nanoparticle conjugated with a peptide consisting of SEQ ID NO: 1, according to any of the previous claims, characterized in that it comprises a chemical compound or radioisotopes which allows the detection of the nanoparticle by in vivo molecular imaging techniques. 5. Nanoparticle conjugated with a peptide consisting of SEQ ID NO: 1, according to any of the previous claims, for use as a medicament. 6. Nanoparticle conjugated with a peptide consisting of SEQ ID NO: 1 for use, according to claim 5, in the prevention and/or treatment of cardiac damage arising after ischemia followed by reperfusion. 7. Nanoparticle conjugated with a peptide consisting of SEQ ID NO: 1 for use, according to claim 6, in the prevention and/or treatment of the inflammatory response following acute myocardial infarction. 8. Pharmaceutical composition comprising the nanoparticle conjugated with a peptide consisting of SEQ ID NO: 1 of any of the claims 1 to 4, and, optionally, pharmaceutically acceptable excipients or carriers. 9. Pharmaceutical composition, according to claim 8, for use in the prevention and/or treatment of cardiac damage arising after ischemia followed by reperfusion. 10. Pharmaceutical composition, according to claim 8, for use, according to claim 9, in the prevention and/or treatment of the inflammatory response following acute myocardial infarction.